Complete and Sustained Objective Response Per RECIST to Irvalec (PM02734) in Undifferentiated Large Cell Esophageal Adenocarcinoma: A Case Report and a Review of the Literature

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2012 Jul 19

PMID 22807904

Citations 3

Authors

Ramon Salazar

Carmen Cuadra

Marta Gil-Martin

Andrea Vandermeeren

Vicente Alfaro

Cinthya Coronado

Affiliations

Soon will be listed here.

Abstract

Undifferentiated large cell carcinoma is a rare entity in esophageal cancer and very few data are available in the literature on this uncommon histological subtype. We report a case of a 58-year-old Caucasian male previously treated with cisplatin/5-fluorouracil, docetaxel and carboplatin/plitidepsin who received treatment with a novel antitumor agent, Irvalec (PM02734), as fourth line. The patient received treatment from July 2006 to July 2009, a total of 49 cycles, at a dose of 2.4 mg/m(2) as a 24-hour infusion every 3 weeks. He did not present severe complications or unplanned or cumulative toxicities. Complete and durable response according to RECIST was reported. He was alive at the last follow-up on March 2012.

Citing Articles

Undifferentiated carcinoma of the esophagus: a clinicopathological study of 16 cases.

Singhi A, Seethala R, Nason K, Foxwell T, Roche R, McGrath K Hum Pathol. 2015; 46(3):366-75.

PMID: 25582499 PMC: 4384179. DOI: 10.1016/j.humpath.2014.11.021.

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.

Goldwasser F, Faivre S, Alexandre J, Coronado C, Fernandez-Garcia E, Kahatt C Invest New Drugs. 2014; 32(3):500-9.

PMID: 24395456 DOI: 10.1007/s10637-013-0060-7.

Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.

Kiraly A, Varadi T, Hajdu T, Ruhl R, Galmarini C, Szollosi J Mar Drugs. 2013; 11(12):4858-75.

PMID: 24317474 PMC: 3877891. DOI: 10.3390/md11124858.

References

Walker A . Identification of esophageal cancer in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2011; 20(11):1159-67. DOI: 10.1002/pds.2249. View

Muijs C, Beukema J, Mul V, Plukker J, Sijtsema N, Langendijk J . External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma. Radiother Oncol. 2011; 102(2):303-8. DOI: 10.1016/j.radonc.2011.07.021. View

Kok T, Nooter K, Smits H, Ter Schegget J . No evidence of known types of human papillomavirus in squamous cell cancer of the oesophagus in a low-risk area. Rotterdam Oesophageal Tumour Study Group. Eur J Cancer. 1998; 33(11):1865-8. DOI: 10.1016/s0959-8049(97)85984-9. View

Choong N, Mauer A, Haraf D, Ferguson M, Sandler A, Kesler K . Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2010; 28 Suppl 1:S152-61. DOI: 10.1007/s12032-010-9658-1. View

Schlansky B, Dimarino Jr A, Loren D, Infantolino A, Kowalski T, Cohen S . A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther. 2006; 23(5):587-93. DOI: 10.1111/j.1365-2036.2006.02782.x. View

Nemoto H, Takeuchi S, Nagasaki H, Yoshizawa Y, Kikuchi H, Yagi H . [Complete remission of esophageal undifferentiated carcinoma with nedaplatin and 5-FU chemotherapy and endoesophageal brachytherapy]. Gan To Kagaku Ryoho. 2003; 30(2):263-7. View

Mori S, Tagaya N, Hamada K, Nakagawa A, Sawada T, Honma K . Undifferentiated carcinoma of the esophagus with rapid growth of lymph node. A case report and review of the literature. Tumori. 2008; 94(3):411-5. DOI: 10.1177/030089160809400319. View

Ilson D . Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2009; 2(2):85-92. PMC: 2630822. View

Trivers K, Sabatino S, Stewart S . Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer. 2008; 123(6):1422-8. DOI: 10.1002/ijc.23691. View

10.

Safieddine N, Xu W, Quadri S, Knox J, Hornby J, Sulman J . Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J Thorac Cardiovasc Surg. 2009; 137(1):36-42. DOI: 10.1016/j.jtcvs.2008.09.049. View

11.

Sgourakis G, Gockel I, Karaliotas C, Moehler M, Schimanski C, Schmidberger H . Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. BMC Cancer. 2012; 12:70. PMC: 3305548. DOI: 10.1186/1471-2407-12-70. View

12.

Shimizu K, Takiyama W, Mandai K, Tanada M, Kawabuchi Y, Heike Y . Undifferentiated carcinoma with lymphoid infiltration of the esophagus: a case report. Jpn J Clin Oncol. 2000; 29(10):494-7. DOI: 10.1093/jjco/29.10.494. View

13.

Stahl M, Budach W, Meyer H, Cervantes A . Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v46-9. DOI: 10.1093/annonc/mdq163. View